BERLIN — Bayer and Boehringer Ingelheim provided the first glimpses of how each of their targeted therapies fare as a front-line treatment for HER2-mutant lung cancer patients.
Boehringer Ingelheim's Hernexeos, also known as zongertinib, shrank tumors ...
↧